linifanib   Click here for help

GtoPdb Ligand ID: 5657

Synonyms: ABT 869 | ABT-869
Compound class: Synthetic organic
Comment: Linifanib is a potent, orally active inhibitor of several receptor tyrosine kinases (RTKs), with principal targets being FLT3, CSF1R and VEGFR2.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 4
Rotatable bonds 5
Topological polar surface area 95.83
Molecular weight 375.15
XLogP 4.65
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(Nc1cc(C)ccc1F)Nc1ccc(cc1)c1cccc2c1c(N)n[nH]2
Isomeric SMILES O=C(Nc1cc(C)ccc1F)Nc1ccc(cc1)c1cccc2c1c(N)n[nH]2
InChI InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)
No information available.
Summary of Clinical Use Click here for help
A Phase 3 clinical trial (NCT01009593) assessing linifanib as a therapy for advanced hepatocellular carcinoma (HCC) was terminated.